Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**5-hydroxytryptophan (commonly known as 5-HTP)** is a naturally occurring amino acid and chemical precursor in the biosynthesis of serotonin and melatonin from tryptophan. It is produced commercially from the seeds of the African plant Griffonia simplicifolia. As a supplement, it is used to increase serotonin levels in the brain, which may influence mood, sleep, appetite, pain sensation, and behavior. Its primary mechanism involves serving as a direct precursor to serotonin by crossing the blood-brain barrier and being decarboxylated to serotonin in presynaptic neurons. While it has been studied for depression (with some evidence suggesting possible effectiveness), its use for other conditions such as anxiety, insomnia, obesity/weight loss, fibromyalgia, Parkinson's disease, headaches/migraines, premenstrual syndrome (PMS), Down syndrome, alcohol withdrawal symptoms, Alzheimer's disease-related symptoms and sleep disorders remains less substantiated or unproven. It is not FDA-approved for any indication[1][2][3][4][8].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 5-hydroxytryptophan.